USA – The Food and Drug Administration (FDA) has given a positive nod to abemaciclib (Verzenio) in combination with endocrine therapy for adjuvant treatment of certain patients with early breast cancer. The approval applies to use of the agent by adults with hormone receptor-positive, HER2-negative, node-positive disease at high risk for recurrence who have a Ki-67 score of at least 20% as determined by an FDA-approved test. The FDA noted in announcing the approval that the oral Cyclin Dependent Kinase 4/6 (CDK 4/6) inhibitor is the first to be approved…
Read MoreFDA clears Eli Lilly’s Verzenio for treatment of early breast cancer
